Javascript must be enabled to continue!
Immuohistochemical expression and prognostic significance of PD-L1 and P53 expression in astrocytoma
View through CrossRef
Background
Astrocytoma is the most common brain tumor. The aberrant expression of programmed cell death ligands 1 (PD-L) on tumor cells results in tumor immune evasion with tumor aggressiveness in many cancers.
Materials and methods
Immunohistochemical analysis was used for examining the morphology and the expression of PD-L1 and P53 in 42 cases of astrocytomas. Univariate analysis was used to correlate the protein expression with the variable clinicopathological parameters. Log-rank test was used to compare the survival among the different groups.
Results
PD-L1 positive expression was found in 42.9% (18/42) of patients with astrocytoma. PD-L1 positive expression showed statistically significant association with grade of astrocytoma (
P
=0.003), poor survival (
P
=0.005), and recurrence (P=0.001). P53 high expression was found in 47.6% (20/42) of patients with astrocytoma. P53 high expression showed statistically significant association with grade of astrocytoma (
P
=0.014), survival (
P
=0.032), and recurrence (
P
=0.001). High significant association was detected between PD-L1 positivity and P53 high expression (
P
=0.005).
Conclusion
The high expression of PD-L1 and P53 was associated with higher grade and poor survival in astrocytoma. A significant association between PD-L1 and P53 might emphasize the interaction between P53 and PD-L1 during astrocytoma progression.
Ovid Technologies (Wolters Kluwer Health)
Title: Immuohistochemical expression and prognostic significance of PD-L1 and P53 expression in astrocytoma
Description:
Background
Astrocytoma is the most common brain tumor.
The aberrant expression of programmed cell death ligands 1 (PD-L) on tumor cells results in tumor immune evasion with tumor aggressiveness in many cancers.
Materials and methods
Immunohistochemical analysis was used for examining the morphology and the expression of PD-L1 and P53 in 42 cases of astrocytomas.
Univariate analysis was used to correlate the protein expression with the variable clinicopathological parameters.
Log-rank test was used to compare the survival among the different groups.
Results
PD-L1 positive expression was found in 42.
9% (18/42) of patients with astrocytoma.
PD-L1 positive expression showed statistically significant association with grade of astrocytoma (
P
=0.
003), poor survival (
P
=0.
005), and recurrence (P=0.
001).
P53 high expression was found in 47.
6% (20/42) of patients with astrocytoma.
P53 high expression showed statistically significant association with grade of astrocytoma (
P
=0.
014), survival (
P
=0.
032), and recurrence (
P
=0.
001).
High significant association was detected between PD-L1 positivity and P53 high expression (
P
=0.
005).
Conclusion
The high expression of PD-L1 and P53 was associated with higher grade and poor survival in astrocytoma.
A significant association between PD-L1 and P53 might emphasize the interaction between P53 and PD-L1 during astrocytoma progression.
Related Results
Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells
Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells
Abstract
The tumor suppressor p53 is mutated in more than 50% of all cancers. The transcriptional activity of p53 depends on localization to the nucleus and formatio...
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
Abstract
Abstract 1490
Background:
The tumor suppressor p53 is frequently mutated in human cancer, including acut...
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract
Cancer cases are on the rise globally requiring a deeper understanding of the disease and identification of novel therapeutic targets. Mutations in genes of...
Abstract 829: p53 dimers elicit tumor suppressive activities through an altered metabolic program
Abstract 829: p53 dimers elicit tumor suppressive activities through an altered metabolic program
Abstract
p53 is the most frequently mutated gene in human cancer. As a tetrameric transcription factor, mutation of the p53 Tetramerization Domain (TD) is a mechanis...
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract
The physiological mechanisms that can restore biological activity of mutant p53 is an area of high interest given that mutant p53 expression is observed in ...
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract
Although the main function of p53 is a nuclear transcription factor that has important roles in cell cycle arrest, DNA repair, and apoptosis, p53 can direct...
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
The AP-1 protein complex primarily consists of several proteins from the c-Fos, c-Jun, activating transcription factor (ATF), and Jun dimerization protein (JDP) families. JDP2 has ...
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract
Introduction: Mutant p53 drives several hallmarks of cancer through a gain-of-function oncogenic program. The oncogenicity of mutant p53 includes sustained ...

